Showing results (31-40 of 38) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
ACS Medicinal Chemistry Letters|September 18, 2024
Discovery and Optimization of Aryl Piperidinone Ureas as Selective Formyl Peptide Receptor 2 AgonistsNicholas R Wurtz, Pravin S Shirude, Daniel L Cheney, et al.Cell Metabolism|November 2, 2022
MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesityDong Cheng, Bradley A Zinker, Yi Luo, et al.JACC. Basic to Translational Science|September 1, 2021
Selective FPR2 Agonism Promotes a Proresolution Macrophage Phenotype and Improves Cardiac Structure-Function Post Myocardial InfarctionRicardo A García, John A Lupisella, Bruce R Ito, et al.Journal of Medicinal Chemistry|September 8, 2021
Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic TherapyAndrew K Dilger, Kumar B Pabbisetty, James R Corte, et al.Journal of Medicinal Chemistry|September 19, 2023
Discovery of <b>12</b> (BMS-986172) as a Highly Potent MGAT2 Inhibitor that Achieved Targeted Efficacious Exposures at a Low Human Dose for the Treatment of Metabolic DisordersWei Meng, Robert Brigance, James Mignone, et al.Journal of Medicinal Chemistry|January 24, 2017
Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding ModeElizabeth A Jurica, Ximao Wu, Kristin N Williams, et al.Journal of Medicinal Chemistry|January 10, 2018
Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 AgonistsJun Shi, Zhengxiang Gu, Elizabeth Anne Jurica, et al.Bioorganic & Medicinal Chemistry|April 8, 2023
Optimization of physicochemical properties of pyrrolidine GPR40 AgoPAMs results in a differentiated profile with improved pharmacokinetics and reduced off-target activitiesElizabeth A Jurica, Ximao Wu, Kristin N Williams, et al.Pageof 4